155 related articles for article (PubMed ID: 30032832)
1. Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
Izumi H; Yamasaki A; Takeda K; Kodani M; Touge H; Tanaka N; Yanai M; Ueda Y; Sakamoto T; Nishii-Ito S; Makino H; Yamaguchi K; Igishi T; Shimizu E
Lung Cancer; 2018 Aug; 122():200-205. PubMed ID: 30032832
[TBL] [Abstract][Full Text] [Related]
2. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
[TBL] [Abstract][Full Text] [Related]
3. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
4. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D
J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated CD25 and Cytokine Expression by γδ T Cells of Systemic Sclerosis Patients Stimulated With Cardiolipin and Zoledronate.
Migalovich Sheikhet H; Villacorta Hidalgo J; Fisch P; Balbir-Gurman A; Braun-Moscovici Y; Bank I
Front Immunol; 2018; 9():753. PubMed ID: 29706966
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate stimulates gamma delta T cells in prostate cancer patients.
Naoe M; Ogawa Y; Takeshita K; Morita J; Shichijo T; Fuji K; Fukagai T; Iwamoto S; Terao S
Oncol Res; 2010; 18(10):493-501. PubMed ID: 20681408
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
9. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of amino-bisphosphonates on circulating γδ T cells.
Rossini M; Adami S; Viapiana O; Fracassi E; Ortolani R; Vella A; Zanotti R; Tripi G; Idolazzi L; Gatti D
Calcif Tissue Int; 2012 Dec; 91(6):395-9. PubMed ID: 23052225
[TBL] [Abstract][Full Text] [Related]
11. Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of γδ T cells.
Takimoto R; Suzawa T; Yamada A; Sasa K; Miyamoto Y; Yoshimura K; Sasama Y; Tanaka M; Kinoshita M; Ikezaki K; Ichikawa M; Yamamoto M; Shirota T; Kamijo R
Immunology; 2021 Mar; 162(3):306-313. PubMed ID: 33131052
[TBL] [Abstract][Full Text] [Related]
12. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
Wang S; Li H; Ye C; Lin P; Li B; Zhang W; Sun L; Wang Z; Xue D; Teng W; Zhou X; Lin N; Ye Z
Front Immunol; 2018; 9():377. PubMed ID: 29535738
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption.
Giusti A; Camellino D; Saverino D; Iervasi E; Girasole G; Bianchi G; Papapoulos SE
Bone; 2020 Sep; 138():115512. PubMed ID: 32603908
[TBL] [Abstract][Full Text] [Related]
14. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
[TBL] [Abstract][Full Text] [Related]
16. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
[TBL] [Abstract][Full Text] [Related]
19. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
20. IL-12 conditioning of peripheral blood mononuclear cells from breast cancer patients promotes the zoledronate-induced expansion of γδ T cells in vitro and enhances their cytotoxic activity and cytokine production.
Assy L; Khalil SM; Attia M; Salem ML
Int Immunopharmacol; 2023 Jan; 114():109402. PubMed ID: 36481526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
